{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:38:43Z","timestamp":1776803923930,"version":"3.51.2"},"reference-count":44,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.schres.2012.06.027","type":"journal-article","created":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T06:30:28Z","timestamp":1342074628000},"page":"214-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis"],"prefix":"10.1016","volume":"140","author":[{"given":"Zeynep","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement C.","family":"Zai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudi","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Arenovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafiris J.","family":"Daskalakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.schres.2012.06.027_bb0005","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.schres.2012.06.027_bb0010","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.npp.1301242","article-title":"Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response\u2014a double-blind PET study in schizophrenia","volume":"32","author":"Agid","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2012.06.027_bb0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/14728214.13.3.479","article-title":"Emerging drugs for schizophrenia","volume":"13","author":"Agid","year":"2008","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"3","key":"10.1016\/j.schres.2012.06.027_bb0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s002130100813","article-title":"In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients","volume":"157","author":"Barnas","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.schres.2012.06.027_bb0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","article-title":"Antipsychotic polypharmacy in schizophrenia: benefits and risks","volume":"25","author":"Barnes","year":"2011","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.schres.2012.06.027_bb0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0925-4927(01)00085-3","article-title":"Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint","volume":"107","author":"Bernardo","year":"2001","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2012.06.027_bb0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00004714-200302000-00002","article-title":"Optimizing limbic selective D2\/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study","volume":"23","author":"Bressan","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2012.06.027_bb0040","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.neuroimage.2010.01.013","article-title":"Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: comparison to 11C-Raclopride PET","volume":"50","author":"Bullich","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.schres.2012.06.027_bb0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacol. Toxicol. (Copenh)"},{"issue":"2","key":"10.1016\/j.schres.2012.06.027_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.neuroimage.2009.02.005","article-title":"Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET","volume":"46","author":"Catafau","year":"2009","journal-title":"Neuroimage"},{"issue":"1","key":"10.1016\/j.schres.2012.06.027_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pnpbp.2004.10.010","article-title":"Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol","volume":"29","author":"Corripio","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2012.06.027_bb0060","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1517\/13543780903066756","article-title":"Drugs in development for the treatment of schizophrenia","volume":"18","author":"Emsley","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.schres.2012.06.027_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00735871","article-title":"An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET","volume":"94","author":"Farde","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.schres.2012.06.027_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0924-977X(00)00133-4","article-title":"D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study","volume":"11","author":"Gefvert","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2012.06.027_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2012.06.027_bb0080","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9618","key":"10.1016\/j.schres.2012.06.027_bb0085","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"Suppl. 9","key":"10.1016\/j.schres.2012.06.027_bb0090","first-page":"35","article-title":"Treatment-resistant schizophrenic patients","volume":"57","author":"Kane","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2012.06.027_bb0095","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2012.06.027_bb0100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2012.06.027_bb0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2012.06.027_bb0115","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2012.06.027_bb0120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","article-title":"A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy","volume":"57","author":"Kapur","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2012.06.027_bb0125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.schres.2012.06.027_bb0130","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"164","author":"Mamo","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2012.06.027_bb0135","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.npp.1301409","article-title":"D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia","volume":"33","author":"Mamo","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2012.06.027_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1749-6632.2011.06216.x","article-title":"Advancing drug discovery for schizophrenia","volume":"1236","author":"Marder","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.schres.2012.06.027_bb0145","first-page":"200","article-title":"Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?","volume":"32","author":"Matthysse","year":"1973","journal-title":"Fed. Proc."},{"issue":"5","key":"10.1016\/j.schres.2012.06.027_bb0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2008-1076727","article-title":"Striatal D2\/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study","volume":"41","author":"Meisenzahl","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/j.schres.2012.06.027_bb0155","first-page":"833","article-title":"LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia","volume":"11","author":"Mezler","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.schres.2012.06.027_bb0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/026988110401800306","article-title":"Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine","volume":"18","author":"Moresco","year":"2004","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2012.06.027_bb0165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archpsyc.55.3.283","article-title":"Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients","volume":"55","author":"Nordstrom","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2012.06.027_bb0170","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.06.027_bb0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Perala","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2012.06.027_bb0180","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/00004850-199705002-00006","article-title":"Amisulpride: from animal pharmacology to therapeutic action","volume":"12","author":"Scatton","year":"1997","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2012.06.027_bb0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mp.4000336","article-title":"Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors","volume":"3","author":"Seeman","year":"1998","journal-title":"Mol. Psychiatry"},{"issue":"5562","key":"10.1016\/j.schres.2012.06.027_bb0190","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.schres.2012.06.027_bb0195","doi-asserted-by":"crossref","first-page":"992","DOI":"10.4088\/JCP.v63n1106","article-title":"Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade","volume":"63","author":"Tauscher-Wisniewski","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2012.06.027_bb0200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.pnpbp.2005.11.027","article-title":"Theoretical insights into the mechanism of action of atypical antipsychotics","volume":"30","author":"Tort","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2012.06.027_bb0205","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4088\/JCP.v69n0811","article-title":"Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia","volume":"69","author":"Uchida","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2012.06.027_bb0210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9690","key":"10.1016\/j.schres.2012.06.027_bb0215","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.schres.2012.06.027_bb0220","first-page":"492","article-title":"The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs","volume":"160","author":"van Rossum","year":"1966","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"issue":"2","key":"10.1016\/j.schres.2012.06.027_bb0225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","article-title":"Polypharmacy in schizophrenia","volume":"23","author":"Zink","year":"2010","journal-title":"Curr. Opin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412003441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412003441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:24:01Z","timestamp":1760297041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996412003441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":44,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0920996412003441"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.06.027","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2012.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}